UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2016
Commission File Number: 001-32001
Aptose Biosciences Inc.
(Translation of registrant's name into English)
5955 Airport Road, Suite 228
Mississauga, ON
L4V 1R9
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On June 21, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated June 21, 2016
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aptose Biosciences Inc. | ||
| (Registrant) | ||
| Date: June 21, 2016 | /s/ Gregory K. Chow | |
| Gregory K. Chow | ||
| Senior Vice President and Chief Financial Officer | ||
EXHIBIT 99.1
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
SAN DIEGO and TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) (“Aptose” or the “Company”) today announced the voting results from the Company’s annual meeting of shareholders held on June 21st in Toronto, Ontario, Canada (the “Meeting”).
The Company is pleased to announce that all of the nominees listed in the management proxy circular dated May 13, 2016 were elected as directors. Each of the directors was elected with greater than 99% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:
| Nominee | Votes For | % Votes For | Votes Withheld | % Votes | ||||
| Withheld | ||||||||
| Dr. Denis Burger | 6,971,868 | 99.79 | 14,813 | 0.21 | ||||
| Dr. Erich Platzer | 6,971,779 | 99.79 | 14,902 | 0.21 | ||||
| Dr. William G. Rice | 6,947,058 | 99.43 | 39,623 | 0.57 | ||||
| Dr. Bradley Thompson | 6,966,495 | 99.71 | 20,186 | 0.29 | ||||
| Dr. Mark D. Vincent | 6,971,878 | 99.79 | 14,803 | 0.21 | ||||
| Warren Whitehead | 6,971,468 | 99.78 | 15,213 | 0.22 | ||||
Aptose shareholders also voted to re-appoint KPMG LLP as auditor of the Company.
A total of 57.4% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
Please refer to the Company’s management proxy circular available on SEDAR at www.sedar.com or EDGAR https://www.sec.gov/edgar.shtml for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR and EDGAR.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
gchow@aptose.com
BCC Partners
Karen L. Bergman or Susan Pietropaolo
650-575-1509 or 845-638-6290
kbergman@bccpartners.com or spietropaolo@bccpartners.com